NASDAQ:TNGX Tango Therapeutics (TNGX) Stock Price, News & Analysis → Trump just won 2024 (From Porter & Company) (Ad) Free TNGX Stock Alerts $7.29 -0.41 (-5.32%) (As of 03:58 PM ET) Add Compare Share Share Today's Range$7.20▼$7.8150-Day Range$7.31▼$11.8052-Week Range$2.47▼$13.03Volume655,476 shsAverage Volume639,283 shsMarket Capitalization$778.13 millionP/E RatioN/ADividend YieldN/APrice Target$17.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Tango Therapeutics alerts: Email Address Tango Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside137.3% Upside$17.25 Price TargetShort InterestBearish19.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$2.10 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.71 out of 5 starsMedical Sector847th out of 919 stocksPharmaceutical Preparations Industry392nd out of 417 stocks 3.5 Analyst's Opinion Consensus RatingTango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTango Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted19.37% of the float of Tango Therapeutics has been sold short.Short Interest Ratio / Days to CoverTango Therapeutics has a short interest ratio ("days to cover") of 17.6, which indicates bearish sentiment.Change versus previous monthShort interest in Tango Therapeutics has recently increased by 4.32%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTango Therapeutics does not currently pay a dividend.Dividend GrowthTango Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TNGX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Tango Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tango Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,103,703.00 in company stock.Percentage Held by InsidersOnly 6.20% of the stock of Tango Therapeutics is held by insiders.Percentage Held by Institutions78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tango Therapeutics are expected to remain at ($1.28) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tango Therapeutics is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tango Therapeutics is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTango Therapeutics has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump just won 2024President Trump signed an executive order that ensures he’ll be remembered as one of America’s greatest Presidents. It was an Executive Order that received almost no media attention…For the full story, click here. About Tango Therapeutics Stock (NASDAQ:TNGX)Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.Read More TNGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TNGX Stock News HeadlinesApril 21, 2024 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Trading Down 3.8%April 1, 2024 | businesswire.comTango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | Porter & Company (Ad)Trump just won 2024President Trump signed an executive order that ensures he’ll be remembered as one of America’s greatest Presidents. It was an Executive Order that received almost no media attention…March 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Tango Therapeutics on Strong Pipeline and Financial StabilityMarch 20, 2024 | finance.yahoo.comTango Therapeutics Inc (TNGX) Reports Full Year and Q4 2023 Financial ResultsMarch 18, 2024 | investorplace.comTNGX Stock Earnings: Tango Therapeutics Misses EPS, Misses Revenue for Q4 2023March 18, 2024 | benzinga.comRecap: Tango Therapeutics Q4 EarningsMarch 11, 2024 | finance.yahoo.comTNGX Aug 2024 20.000 putMay 1, 2024 | Porter & Company (Ad)Trump just won 2024President Trump signed an executive order that ensures he’ll be remembered as one of America’s greatest Presidents. It was an Executive Order that received almost no media attention…March 6, 2024 | businesswire.comTango Therapeutics to Participate in Upcoming Investor ConferencesMarch 5, 2024 | globenewswire.comTango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024March 3, 2024 | finance.yahoo.comCompanies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In GrowthFebruary 17, 2024 | finance.yahoo.comTNGX Mar 2024 7.500 callFebruary 17, 2024 | finance.yahoo.comTNGX Mar 2024 12.500 callJanuary 31, 2024 | finance.yahoo.comTango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceJanuary 7, 2024 | seekingalpha.comTango Therapeutics Must Produce Its Own Data To Justify Its ValuationJanuary 4, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Tango Therapeutics (TNGX), Esperion (ESPR)January 4, 2024 | finance.yahoo.comMedivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical studyJanuary 3, 2024 | finance.yahoo.comTango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ CancersDecember 13, 2023 | finance.yahoo.comSubdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 25%December 8, 2023 | msn.comB. Riley Securities Initiates Coverage of Tango Therapeutics (TNGX) with Buy RecommendationDecember 8, 2023 | realmoney.thestreet.comTango Therapeutics initiated with a Buy at B. RileyDecember 8, 2023 | finance.yahoo.comWall Street Analysts Predict an 110.53% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should KnowNovember 13, 2023 | finance.yahoo.comHow Much Upside is Left in Tango Therapeutics, Inc. (TNGX)? Wall Street Analysts Think 115.31%November 13, 2023 | finance.yahoo.comTango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual MeetingNovember 10, 2023 | markets.businessinsider.comPositive Outlook for Tango Therapeutics: Comprehensive Analysis of Ongoing Clinical Trials and Promising PRMT5 InhibitorsNovember 10, 2023 | markets.businessinsider.comPositive Financial Performance and Promising Drug Development Bolster Tango Therapeutics’ Buy RatingSee More Headlines Receive TNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/01/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TNGX CUSIPN/A CIK1819133 Webwww.tangotx.com Phone857-320-4900FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Stock Price Target$17.25 High Stock Price Target$18.00 Low Stock Price Target$16.00 Potential Upside/Downside+123.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,740,000.00 Net Margins-278.55% Pretax Margin-278.18% Return on Equity-41.96% Return on Assets-25.22% Debt Debt-to-Equity RatioN/A Current Ratio7.54 Quick Ratio7.54 Sales & Book Value Annual Sales$36.53 million Price / Sales22.59 Cash FlowN/A Price / Cash FlowN/A Book Value$2.48 per share Price / Book3.12Miscellaneous Outstanding Shares106,740,000Free Float100,117,000Market Cap$825.10 million OptionableOptionable Beta0.83 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Barbara L. Weber M.D. (Age 66)President, CEO & Director Comp: $941.16kMs. Daniella Beckman CPA (Age 45)Chief Financial Officer Comp: $619.13kDr. Alan Ashworth FRS (Age 62)Ph.D., Founder & Member of Scientific Advisory Board Dr. Levi Garraway M.D. (Age 55)Ph.D., Founder Dr. William G. Kaelin Jr. (Age 66)M.D., Founder & Member of Scientific Advisory Board Dr. Timothy K. Lu M.D. (Age 43)Ph.D., Founder Dr. Antoni Ribas M.D. (Age 57)Ph.D., Founder & Member of Scientific Advisory Board Mr. Jannik N. Andersen Ph.D.Chief Scientific OfficerMr. Douglas J. Barry Esq. (Age 53)J.D., Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Mr. John C. Ross M.S.Vice President of Human ResourcesMore ExecutivesKey CompetitorsEnliven TherapeuticsNASDAQ:ELVN89bioNASDAQ:ETNBArcutis BiotherapeuticsNASDAQ:ARQTSage TherapeuticsNASDAQ:SAGEImmunomeNASDAQ:IMNMView All CompetitorsInsiders & InstitutionsMirae Asset Global Investments Co. Ltd.Bought 7,128 shares on 5/1/2024Ownership: 0.027%China Universal Asset Management Co. Ltd.Bought 7,776 shares on 4/29/2024Ownership: 0.018%Simplicity Wealth LLCBought 26,961 shares on 4/24/2024Ownership: 0.025%Fishman Jay A Ltd. MIBought 10,000 shares on 4/23/2024Ownership: 0.022%Mass General Brigham IncBought 354,192 shares on 4/4/2024Ownership: 0.332%View All Insider TransactionsView All Institutional Transactions TNGX Stock Analysis - Frequently Asked Questions Should I buy or sell Tango Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNGX shares. View TNGX analyst ratings or view top-rated stocks. What is Tango Therapeutics' stock price target for 2024? 5 analysts have issued 12-month price objectives for Tango Therapeutics' stock. Their TNGX share price targets range from $16.00 to $18.00. On average, they expect the company's stock price to reach $17.25 in the next year. This suggests a possible upside of 137.3% from the stock's current price. View analysts price targets for TNGX or view top-rated stocks among Wall Street analysts. How have TNGX shares performed in 2024? Tango Therapeutics' stock was trading at $9.90 at the beginning of the year. Since then, TNGX stock has decreased by 26.6% and is now trading at $7.27. View the best growth stocks for 2024 here. When is Tango Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our TNGX earnings forecast. How were Tango Therapeutics' earnings last quarter? Tango Therapeutics, Inc. (NASDAQ:TNGX) released its earnings results on Monday, March, 18th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.04. The business earned $5.43 million during the quarter, compared to the consensus estimate of $7.86 million. Tango Therapeutics had a negative trailing twelve-month return on equity of 41.96% and a negative net margin of 278.55%. Who are Tango Therapeutics' major shareholders? Tango Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Mass General Brigham Inc (0.33%), Mirae Asset Global Investments Co. Ltd. (0.03%), Simplicity Wealth LLC (0.03%), Fishman Jay A Ltd. MI (0.02%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Adam Crystal, Barbara Weber, Boxer Capital, Llc, Daniella Beckman, Douglas Barry and Rock Ventures Iv LP Third. View institutional ownership trends. How do I buy shares of Tango Therapeutics? Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TNGX) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerNvidia CEO Says It Will Be “the Next Revolution” Beyond AIBanyan Hill PublishingForget Nvidia. This is the future of AIPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
